ADC-话题@MedSci

#ADC#

2篇内容 | 1116人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2197754, encodeId=1f3a219e754b8, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a> <a href='/topic/show?id=85de5518160' target=_blank style='color:#2F92EE;'>#抗体偶联药物#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=超40%患者6个月疾病无进展！周彩存教授：新一代ADC对乳腺癌、肺癌等有效 | 2024 AACR, objectType=article, longId=819548, objectId=05cf81954849, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/conference-with-doctors-in-medical-aprons-PT29AAG.jpg, objectUrl=/article/show_article.do?id=05cf81954849, replyNumber=0, likeNumber=8, createdTime=2024-04-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=05cf81954849, moduleTitle=超40%患者6个月疾病无进展！周彩存教授：新一代ADC对乳腺癌、肺癌等有效 | 2024 AACR, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05cf81954849)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2197229, encodeId=3cfb219e22950, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=《柳叶刀》子刊：疾病控制率达80%，重磅ADC有望填补肺癌治疗空白, objectType=article, longId=819216, objectId=721c8192162c, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/prescription-form-with-medical-stethoscope-9ZRKVHM.jpg, objectUrl=/article/show_article.do?id=721c8192162c, replyNumber=0, likeNumber=9, createdTime=2024-04-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=721c8192162c, moduleTitle=《柳叶刀》子刊：疾病控制率达80%，重磅ADC有望填补肺癌治疗空白, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=721c8192162c)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194527, encodeId=cfba219452e49, content=<a href='/topic/show?id=39f911253806' target=_blank style='color:#2F92EE;'>#HLX43#</a> <a href='/topic/show?id=739311253952' target=_blank style='color:#2F92EE;'>#靶向PD-L1#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a> <a href='/topic/show?id=49ed460213b' target=_blank style='color:#2F92EE;'>#实体肿瘤#</a>, objectTitle=高配版本的ADC抗癌药，靶向PD-L1的抗体偶联药HLX43可用于多种实体肿瘤，首个患者开始用药！, objectType=article, longId=817402, objectId=b36981e402e6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, objectUrl=/article/show_article.do?id=b36981e402e6, replyNumber=0, likeNumber=12, createdTime=2024-03-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b36981e402e6, moduleTitle=高配版本的ADC抗癌药，靶向PD-L1的抗体偶联药HLX43可用于多种实体肿瘤，首个患者开始用药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b36981e402e6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2191252, encodeId=a08221912525a, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=【专家访谈】“问题ADC”大盘点，讲讲这些药物如何加入非小细胞肺癌的“治疗革命”, objectType=article, longId=815989, objectId=33f7815989c2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/hospital-staff-at-work-PGMH47J.jpg, objectUrl=/article/show_article.do?id=33f7815989c2, replyNumber=0, likeNumber=16, createdTime=2024-03-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=33f7815989c2, moduleTitle=【专家访谈】“问题ADC”大盘点，讲讲这些药物如何加入非小细胞肺癌的“治疗革命”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33f7815989c2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174007, encodeId=076e21e400709, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=87b99316273' target=_blank style='color:#2F92EE;'>#踝关节#</a> <a href='/topic/show?id=bdee50021b4' target=_blank style='color:#2F92EE;'>#弥散加权显像#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=European Radiology：弥散加权MR成像和ADC测量在糖尿病患者踝关节DWI研究的应用, objectType=article, longId=804205, objectId=2a168042059b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231208/1702020703381_1605392.png, objectUrl=/article/show_article.do?id=2a168042059b, replyNumber=0, likeNumber=56, createdTime=2023-12-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2a168042059b, moduleTitle=European Radiology：弥散加权MR成像和ADC测量在糖尿病患者踝关节DWI研究的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a168042059b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2169956, encodeId=aed3216995697, content=<a href='/topic/show?id=73c423e2572' target=_blank style='color:#2F92EE;'>#乳腺癌#</a> <a href='/topic/show?id=0650803e21a' target=_blank style='color:#2F92EE;'>#耐药#</a> <a href='/topic/show?id=2cf09992871' target=_blank style='color:#2F92EE;'>#靶向疗法#</a> <a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>, objectTitle=综述：“革命性”药物为癌症患者带来希望，七大策略战胜耐药挑战！, objectType=article, longId=801665, objectId=525e801665a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-staff-meeting-GXNVP9J.jpg, objectUrl=/article/show_article.do?id=525e801665a2, replyNumber=0, likeNumber=41, createdTime=2023-11-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=525e801665a2, moduleTitle=综述：“革命性”药物为癌症患者带来希望，七大策略战胜耐药挑战！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525e801665a2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2116718, encodeId=f0bd2116e1803, content=<a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>类药物, objectTitle=又一款重磅ADC来到中国！细数全球获批的14款ADC, objectType=article, longId=756140, objectId=afc0e56140f9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668025636625_4754896.webp, objectUrl=/article/show_article.do?id=afc0e56140f9, replyNumber=0, likeNumber=57, createdTime=2023-02-27, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=afc0e56140f9, moduleTitle=又一款重磅ADC来到中国！细数全球获批的14款ADC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afc0e56140f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1247599, encodeId=d40f124e5998b, content=<a href='/topic/show?id=6d448341139' target=_blank style='color:#2F92EE;'>#胃食管腺癌#</a><a href='/topic/show?id=e3818e1893' target=_blank style='color:#2F92EE;'>#HER2#</a><a href='/topic/show?id=2ad83e51258' target=_blank style='color:#2F92EE;'>#双特异性抗体#</a>，如果这个抗体将来再接一个细胞毒的，做成<a href='/topic/show?id=6f6c19562f' target=_blank style='color:#2F92EE;'>#ADC#</a>类，会不会效果更好？？, objectTitle=治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”, objectType=article, longId=259632, objectId=614325963215, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220901/fd150596f89f4c9aab6627cae756b797.jpg, objectUrl=/article/show_article.do?id=614325963215, replyNumber=0, likeNumber=87, createdTime=2022-09-07, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614325963215, moduleTitle=治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614325963215)], followStatus=false, userIsMember=true, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #肺癌# #AACR# #抗体偶联药物# #ADC#

超40%患者6个月疾病无进展！周彩存教授：新一代ADC对乳腺癌、肺癌等有效 | 2024 AACR

2024-04-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#肺癌# #ADC#

《柳叶刀》子刊：疾病控制率达80%，重磅ADC有望填补肺癌治疗空白

2024-04-07发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#HLX43# #靶向PD-L1# #ADC# #实体肿瘤#

高配版本的ADC抗癌药，靶向PD-L1的抗体偶联药HLX43可用于多种实体肿瘤，首个患者开始用药！

2024-03-21发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #ADC#

【专家访谈】“问题ADC”大盘点，讲讲这些药物如何加入非小细胞肺癌的“治疗革命”

2024-03-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #踝关节# #弥散加权显像# #ADC#

European Radiology：弥散加权MR成像和ADC测量在糖尿病患者踝关节DWI研究的应用

2023-12-10发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乳腺癌# #耐药# #靶向疗法# #ADC#

综述：“革命性”药物为癌症患者带来希望，七大策略战胜耐药挑战！

2023-11-21发表于上海

showtest (审核中...)

前往app查看评论内容

#ADC#类药物

又一款重磅ADC来到中国！细数全球获批的14款ADC

2023-02-27发表于上海

(审核中...)

前往app查看评论内容

#胃食管腺癌##HER2##双特异性抗体#，如果这个抗体将来再接一个细胞毒的，做成#ADC#类，会不会效果更好？？

治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”

2022-09-07

科室
- - 订阅+
  - 更多科室
工具
服务